This observational prospective study will help to determine if an immune process similar to allograft rejection is responsible for the occurrence of an intrahepatic cholestasis of pregnancy (ICP).

If so, it would suggest the potential benefit of immunomodulatory therapeutics.

This observational study will include 322 pregnant women at delivery: 161 women diagnosed with an intrahepatic cholestasis of pregnancy, and 161 control women.

A blood test will be performed at delivery for each woman and each newborn, in order to measure several biological parameters involved in inflammation processes, allograft rejection and angiogenesis. Placenta will also be analysed. In particular, we will look for chronic inflammation in placenta.

Biological parameters and placental parameters will be compared between the two groups: cases with ICP and controls.

Inclusion Criteria:

• Adult pregnant woman with singleton

For cases: diagnosis of intrahepatic cholestasis of pregnancy For controls: no diagnosis of ICP

Exclusion Criteria:

• Women under 18 years old
• Women under legal protection
• Gemellar pregnancies
• Delivery before 22 Weeks of gestation
• Medical termination of pregnancy
• Acute chorioamniotitis, in particular those due to the following pathogens: toxoplasmosis, rubella, CMV, herpes virus
• Premature rupture of membranes <37SA
• Women infected by covid-19 in the month before delivery

Pregnant woman

Pregnant women with or without intrahepatic cholestasis of pregnancy included at delivery.

Each control will be matched with each case according to gestation age at delivery.

All collected data that underlie results in a publication

Data will be available beginning two years and ending five years following the publication

Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.